Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01267331
Other study ID # 2006AA02A104
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received December 23, 2010
Last updated January 11, 2011
Start date December 2010
Est. completion date June 2013

Study information

Verified date December 2010
Source Chinese PLA General Hospital
Contact Changqing Gao, MD
Phone +8601066938035
Email gaochq301@yahoo.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

This prospective, randomized, placebo-controlled study was designed to assess the safety, feasibility and efficacy of intramyocardial injection of autologous bone marrow mononuclear cells in patients with severe, chronic ischemic disease scheduled to coronary artery bypass surgery.


Description:

Severe ischemic heart disease remains a clinical challenge; many patients have undergone surgical myocardial revascularization procedures, but still remain symptomatic despite optimal medical therapy. Cell therapy with autologous bone marrow-derived cells (BMC) is a novel therapeutic strategy being tested for surgical treatment in patients with severe, chronic ischemic heart disease.

This research study is being performed to find out more information about the safety, feasibility, and efficacy of direct intramyocardial injection of autologous BMC on the myocardial perfusion and left ventricular function as an adjunctive therapy (compared to placebo) in patients undergoing coronary artery bypass surgery (CABG). The heart function evaluations will be performed by electrocardiogram, echocardiogram, and cMRI at baseline and during 6 months follow-up.

The secondary objective of this study is to assess the effect of intramyocardial injection of autologous BMC on functional class (angina/heart failure), global and cardiovascular mortality, and major adverse cardiac events after undergoing coronary artery bypass surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age between 18 and 75 years.

2. Scheduled to undergo CABG.

3. At least 3 months since last episode of myocardial infarction.

4. Echocardiogram-assessed LVEF between 15 and 40% (Simpson's rule).

5. Abnormal wall motion of at least one segment due to prior myocardial infarction shown by echocardiography or left ventriculography.

6. Abnormal myocardial perfusion in infarcted area by SPECT.

7. Willingness to participate and ability to provide written informed consent.

Exclusion Criteria:

1. Contraindications to magnetic resonance imaging.

2. Need for urgent or emergent revascularization.

3. Severe valvular heart disease.

4. Confirmed myocardial infarction within 14 days, and/or rising cardiac biomarker proteins (i.e. troponin), and/or worsening ECG changes.

5. Prior cardiac surgery.

6. Stroke within 3 months prior to CABG.

7. Immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)

8. Severe chronic renal insufficiency (serum creatinine = 200 mmol/dl or need for dialysis), liver disease, (diagnosis of cirrhosis, chronic hepatitis, or elevation of serum transaminases =3 times the upper limit of normal), cerebrovascular disease requiring concomitant carotid endarterectomy, peripheral arterial disease (claudication as the primary factor limiting activity), active non-dermatological malignancy requiring on-going treatment, or any other condition that would place the patient at increased risk for complications in the judgment of the attending cardiologist or cardiac surgeon

9. Hemoglobin less than 10g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3

10. Active infection, with a temperature greater than 37.5°C within 48 hrs prior to surgery and an unexplained white blood cell count in excess of 10,000/mm3

11. Significant cognitive impairment.

12. Any condition associated with a life expectancy of less than 6 months.

13. Participation in other studies.

14. Positive laboratory test results for HIV, HBC, and HCV.

15. Pregnant woman.

16. Inability or unwillingness to provide written informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment


Intervention

Procedure:
bone marrow mononuclear cells injection
Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
placebo intramyocardial injection
Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.

Locations

Country Name City State
China Chinese PLA General Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary major adverse cardiac events Freedom from Major Adverse Cardiac Event: cardiac death, myocardial infarction, repeat coronary bypass grafting or percutaneous intervention of bypassed artery 6 months Yes
Secondary left ventricular function Globlal function,regional myocardial perfusion and function assessed by magnetic resonance iamge and echocardiogram 6 months No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05529654 - IMpella-Protected cArdiaC Surgery Trial (IMPACT) N/A
Recruiting NCT04671966 - Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction Phase 4
Not yet recruiting NCT05188222 - Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery Phase 4
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT01076920 - Mesenchymal Stem Cells and Myocardial Ischemia Phase 1/Phase 2
Completed NCT01128790 - Pilot Study of Remote Ischemic Preconditioning in Heart Failure N/A
Completed NCT04942353 - Effects of Home-based Exercise Rehabilitation on Healthcare Utilization in HeartMate 3 Patients N/A
Recruiting NCT05769036 - Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients N/A
Completed NCT03232736 - InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
Recruiting NCT04694092 - Landiolol for Rate Control in Decompensated Heart Failure Due to Atrial Fibrillation N/A
Completed NCT02013037 - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Phase 3
Completed NCT01609738 - Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum Phase 1/Phase 2
Completed NCT00551681 - Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure N/A
Not yet recruiting NCT04103008 - Left Ventricular Function After Primary Percutaneous Coronary Intervention: Role of Speckle Echocardiography
Completed NCT06197256 - Cardiac Dysfunction in Critically Ill Covid-19 Patients
Recruiting NCT05860504 - Acute Cardiac Dysfunction in Critical Illnes
Completed NCT03787810 - Left Ventricular Dysfunction in Critically Ill Patients
Completed NCT01093001 - Tricuspid Regurgitation Study Phase 4
Active, not recruiting NCT00461734 - PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing N/A
Recruiting NCT04752293 - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)